Where does Exonhit Therapeutics, SA rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Exonhit Therapeutics, SA ranks #46,631 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Exonhit Therapeutics, SA hold?

Exonhit Therapeutics, SA holds 5 US utility patents granted between 2015 and 2018, spanning 4 technology areas.

What is Exonhit Therapeutics, SA's Innovation Score?

Exonhit Therapeutics, SA has an Innovation Score of 18.5 out of 100 (5th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Exonhit Therapeutics, SA focus on?

Exonhit Therapeutics, SA's top technology area is C07D (Heterocyclic Compounds) with 5 patents. Grants appear in 4 CPC subclasses total.

Is Exonhit Therapeutics, SA's patent grant rate increasing or decreasing?

Exonhit Therapeutics, SA's recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Exonhit Therapeutics, SA's patents?

Exonhit Therapeutics, SA's patents average 8.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Exonhit Therapeutics, SA patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Exonhit Therapeutics, SA

USPTO PatentsView assignee record - 5 granted patents across 4 technology areas, recorded in grant years 2015–2018. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Exonhit ranks #46,631 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 4 technology areas.

#46,631
of 49,997 US assignees by volume: 5th percentile
by Innovation Score (18.5/100): 8.8
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R46631 · Foreign Corporation #46,631 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-LOW · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 5 grants
BOTTOM-DECILE #46,631/49,997
PHOTO-FINISH Exelway
CPC-NARROW C07D · 4 areas
INNOV-LOW 18.5/100
CLAIMS-PAR 8.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Exelway Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Exonhit Therapeutics · this assignee

19
3D Lighting… · lowest

7

What this shows Exonhit's Innovation Score is 18.5/100 (5th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Exonhit's grants concentrate

Exonhit Therapeutics, SA is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2017 (2 grants) versus a trough of 1 in 2015. By volume, Exonhit sits between Exelway Inc. and Expanded Existence, Inc..

Exelway

5
Exhalation Techno…

5
Exhaustless

5
Exoiq

5
Exostemtech

5
Exotec Solutions

5
Exotex

5
Expanded Existence

5
Exonhit Therapeut… ◀

5

What this shows Exonhit holds 5 patents at rank #46,491, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Exonhit

By rank, the assignees closest to #46,491 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Exonhit's primary technology class.

Exonhit's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

19 5th percentile higher than 5% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2018

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Exonhit Therapeutics, SA patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	20.0%
2016	1	20.0%
2017	2	40.0%
2018	1	20.0%

Which technologies does Exonhit Therapeutics, SA patent most?

C07D - Heterocyclic Compounds 5

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 2

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#46,631

of 49,997 tracked assignees

Innovation Score

18.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Exonhit Therapeutics, SA's patent record in context - here's where to go next.

Exonhit Therapeutics, SA's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #46,631 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Exonhit Therapeutics, SA against Exelway Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 18.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.